Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,183
Out of 5,152 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $34.00 | +23.53% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $175.60 | +113.55% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $80.20 | +43.39% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $82.52 | +11.49% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $18.58 | -35.41% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $14.25 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $71.36 | +26.12% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $238.51 | +13.20% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $112.10 | -39.34% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $13.79 | +226.32% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $117.57 | +133.90% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $18.57 | +99.25% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $70.69 | -15.12% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $72.99 | -52.05% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $240.94 | -66.38% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $34.00
Upside: +23.53%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $175.60
Upside: +113.55%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $80.20
Upside: +43.39%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $82.52
Upside: +11.49%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $18.58
Upside: -35.41%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $14.25
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $71.36
Upside: +26.12%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $238.51
Upside: +13.20%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $112.10
Upside: -39.34%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $13.79
Upside: +226.32%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $117.57
Upside: +133.90%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $18.57
Upside: +99.25%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $70.69
Upside: -15.12%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $72.99
Upside: -52.05%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $240.94
Upside: -66.38%